anthropic Anthropic Launches Claude Science Platform and Plans Its Own Drug Development Anthropic announces Claude Science, a new AI workbench designed to help researchers by consolidating fragmented tools and datasets into a single environment. The platform also generates figures and visuals, aiming to streamline scientific workflows. Anthropic touts a long list of biotech and pharmaceutical customers already using Claude and frames the
eli lilly Eli Lilly Strikes $2.75 Billion Deal for AI-Developed Drugs Eli Lilly partners with Insilico Medicine in a massive $2.75 billion agreement to bring artificial intelligence-developed drugs to the global market. The deal highlights the growing role of generative AI in accelerating pharmaceutical discovery and development.
tetsuwan scientific Tetsuwan Scientific Builds AI-Powered Robots to Automate Lab Experiments Tetsuwan Scientific combines low-cost lab robots with large language models to create automated AI scientists that perform and adjust experiments without human intervention. The startup aims to eliminate the tedious manual labor that currently plagues lab technicians.
mdc MDC Builds MRI-Compatible Surgical Robot Using Water-Powered Hydraulics MDC develops a water-powered robotic system that operates directly inside MRI machines to guide surgical needles in real time. The technology eliminates the need to repeatedly move patients in and out of the scanner during procedures.
venture capital Venture Megadeals Surge as Biotech Outpaces AI in Late-Stage Funding Despite a high rate of down rounds, U.S. startups see a boom in $100 million-plus funding rounds in 2024. Surprisingly, biotech and healthcare lead the mega-deal categories, surpassing artificial intelligence.
23andme 23andMe's Decline Raises Serious Questions About Genomic Data Security As 23andMe faces delisting and a plummeting valuation, experts warn that its roughly 15 million customers face unique, irreversible risks if the company fails. Advancing genomic analysis technology makes this unprotected genetic data even more dangerous than standard financial breaches.
y combinator AI Dominates Y Combinator Summer 2024 Demo Day Two Standouts Y Combinator concludes its Summer 2024 Demo Day with a second batch of impressive startups, where artificial intelligence remains the central focus. Notable companies include an energy-efficient AI chip maker and an automated engineering assistant already working with AWS.
23andme 23andMe Board Members Resign En Masse Amid Takeover Stalemate All independent directors at 23andMe abruptly resign after losing faith in CEO Anne Wojcicki's plan to take the company private. The mass departure drops the genomics firm's market cap to a mere $173 million.
ai Cambridge Spinout CardiaTec Raises $6.5M for AI Heart Disease Drug Discovery CardiaTec leverages AI and a massive human heart tissue dataset to find new cardiovascular disease treatments. The Cambridge University spinout secures $6.5 million in seed funding to combat the world's leading cause of death.
venture capital Healthcare and AI Sectors Dominate $23 Billion in July Venture Funding Venture funding totals over $23 billion in July 2024, with healthcare and artificial intelligence companies capturing half of all investments. Notable financial moves include a massive $900 million round for legal tech firm Clio and the year's largest IPO from Lineage Logistics.
nvidia Nvidia Targets Healthcare Industry With New AI Partnerships and Tools Nvidia expands into the healthcare sector through new partnerships with Johnson & Johnson and GE Healthcare, alongside the launch of two dozen AI-powered medical tools. Industry experts note that generative AI offers tangible benefits for drug discovery and medical technology.
biontech BioNTech Acquires AI Firm InstaDeep for $440M to Boost Drug Discovery BioNTech purchases InstaDeep in a deal worth up to £562 million to integrate artificial intelligence across its immunotherapy platforms. The acquisition brings 240 AI and machine learning experts into BioNTech's workforce.
biontech BioNTech Buys AI Startup InstaDeep for $680 Million to Boost Cancer Drug Discovery BioNTech acquires U.K.-based AI startup InstaDeep in a deal worth up to $680 million to advance its personalized cancer treatments. The purchase builds on a previous partnership between the two companies.
ai French Biotech WhiteLab Genomics Raises $10M for AI Gene Therapy Platform WhiteLab Genomics secures $10 million to expand its AI platform that helps scientists design gene and cell therapies through predictive simulations. The technology aims to replace costly trial-and-error methods by predicting the best molecular designs for treating genetic disorders.
insilico Insilico Raises $35M From Aramco Venture Arm For AI Drug Discovery Hong Kong-based Insilico secures $35 million in Series D funding led by Aramco's Prosperity7 to advance its AI-driven drug discovery and sustainable chemistry efforts.